Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525513-31-00

Enrollment

190

Registered

2026-08-17

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small-cell lung cancer, limited stage

Brief summary

Overall survival

Detailed description

Local, intrathoracic control rate, Time to discontinuation of durvalumab therapy, Toxicity, Response rates, Progression free survival, Health related quality of life (HRQoL)

Interventions

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Local, intrathoracic control rate, Time to discontinuation of durvalumab therapy, Toxicity, Response rates, Progression free survival, Health related quality of life (HRQoL)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 19, 2026